This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.
Device | VENTANA MMR RxDx Panel |
Generic Name | Immunohistochemistry Test, Dna Mismatch Repair (mmr) Protein Assay |
Applicant | Ventana Medical Systems Inc (Roche Tissue Diagnostics)1910 E. Innovation Park Drivetucson, AZ 85755 PMA NumberP210001 Supplement NumberS001 Date Received08/18/2021 Decision Date03/21/2022 Product Code QNH Advisory Committee Pathology Clinical TrialsNCT02460198 Supplement Typenormal 180 Day Track Supplement Reason Labeling Change - Indications/instructions/shelf Life/tradename Expedited Review Granted? No |
Date Received | 2021-08-18 |
Decision Date | 2022-03-21 |
PMA | P210001 |
Supplement | S001 |
Product Code | QNH |
Advisory Committee | Pathology |
Supplement Type | Normal 180 Day Track |
Supplement Reason | Labeling Change - Indications/instructions/shelf Life/tradename |
Expedited Review | No |
Combination Product | No |
Applicant Address | Ventana Medical Systems Inc (Roche Tissue Diagnostics) 1910 E. Innovation Park Drive tucson, AZ 85755 PMA NumberP210001 Supplement NumberS001 Date Received08/18/2021 Decision Date03/21/2022 Product Code QNH Advisory Committee Pathology Clinical TrialsNCT02460198 Supplement Typenormal 180 Day Track Supplement Reason Labeling Change - Indications/instructions/shelf Life/tradename Expedited Review Granted? No Combination ProductNo Approval Order Statement Approval For The Ventana MMR RxDx Panel As A CDx For Identifying Patients With Solid Tumors With DMMR Status Who May Benefit From Treatment With KEYTRUDA. |
Supplement Number | Date | Supplement Type |
---|---|---|
P210001 | Original Filing | |
S007 | 2022-10-14 | 30-day Notice |
S006 | 2022-07-12 | 30-day Notice |
S005 | 2022-04-28 | Normal 180 Day Track No User Fee |
S004 | ||
S003 | ||
S002 | ||
S001 | 2021-08-18 | Normal 180 Day Track |